Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 92 of 95, showing 5 Applications out of 474 total, starting on record 456, ending on 460

# Protocol No Study Title Investigator(s) & Site(s)

456.

21/06/16   VAT00008
    A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older   
Principal Investigator(s)
1. Fredrick Sawe
Site(s) in Kenya
1. Kenya Medical Research Institute, Kisumu Clinical Reseach Site (Kisumu county)
2. KEMRI/Walter Reed Project - Clinical Research Center, Kericho (Kericho county)
3. Ganjoni Clinic - University of Washington/University of Nairobi, Mombasa (Mombasa county)
4. Partners in Health Research and Development, Thika (Kiambu county)
5. KARGENO RESEARCH AND POLICY HUB (Kisumu county)
6. The Centre for Respiratory Diseases Research (CRDR), Kenya Medical Research Institute (KEMRI) (Nairobi City county)
7. KEMRI-USAMRD-A/K, Kombewa Clinical Research Center (Kisumu county)
8. Moi University Clinical Research Centre (MUCRC), Chandaria Cancer and Chronic Diseases Center (CCCDC) (Uasin Gishu county)
9. Aga Khan University Hospital (Nairobi City county)
10. KEMRI CCR-Butere County Hospital Site (Kakamega county)
 
View

457.

ECCT/21/07/04   Healthy Route
    A Non-Interventional Pilot Study to Evaluate A Machine-Learning Algorithm for Prediction of Blood Pressure, Glycated Haemoglobin and Estimated Glomerular Filtration Rate from Digital Retinal Images   
Principal Investigator(s)
1. Mansoor Noorali Saleh
2. Videlis Nduba
Site(s) in Kenya
1. Aga Khan University Hospital Clinical Research Unit (Nairobi City county)
2. Kenya Medical Research Institute CRDR (Nairobi City county)
 
View

458.

ECCT/11/04/01  
    A Double-blind, Randomized Trial of Monthly Treatment with Metronidazole and Miconazole Co-formulated Suppositories versus Placebo for Preventing Vaginal Infections in HIVSeronegative Women (DMID Protocol Number: 09-0070)   
Principal Investigator(s)
1. Raymond Scott McClelland
Site(s) in Kenya
1. Kenya AIDS Vaccine Initiative (Nairobi City county)
2. Kenya AIDS Control Program (Nairobi City county)
3. Mombasa HIV/STD Research Clinic (Mombasa county)
 
View

459.

ECCT/21/07/02   TALIOS
    A 3-ARM, RANDOMIZED, BLINDED, ACTIVE-CONTROLLED, PHASE II STUDY OF RO7121661, A PD1-TIM3 BISPECIFIC ANTIBODY AND RO7247669, A PD1-LAG3 BISPECIFIC ANTIBODY, COMPARED WITH NIVOLUMAB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
1. Aga Khan University, Nairobi (Nairobi City county)
2. International Cancer Institute (Uasin Gishu county)
 
View

460.

ECCT/16/10/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Professor Walter Jaoko
Site(s) in Kenya
1. KAVI Institute of Clinical Research (Nairobi City county)
2. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
 
View